Literature DB >> 23152508

Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120.

Julie Matz1, Pascal Kessler, Jérôme Bouchet, Olivier Combes, Oscar Henrique Pereira Ramos, Francis Barin, Daniel Baty, Loïc Martin, Serge Benichou, Patrick Chames.   

Abstract

Few broadly neutralizing antibodies targeting determinants of the HIV-1 surface envelope glycoprotein (gp120) involved in sequential binding to host CD4 and chemokine receptors have been characterized. While these epitopes show low diversity among various isolates, HIV-1 employs many strategies to evade humoral immune response toward these sensitive sites, including a carbohydrate shield, low accessibility to these buried cavities, and conformational masking. Using trimeric gp140, free or bound to a CD4 mimic, as immunogens in llamas, we selected a panel of broadly neutralizing single-domain antibodies (sdAbs) that bind to either the CD4 or the coreceptor binding site (CD4BS and CoRBS, respectively). When analyzed as monomers or as homo- or heteromultimers, the best sdAb candidates could not only neutralize viruses carrying subtype B envelopes, corresponding to the Env molecule used for immunization and selection, but were also efficient in neutralizing a broad panel of envelopes from subtypes A, C, G, CRF01_AE, and CRF02_AG, including tier 3 viruses. Interestingly, sdAb multimers exhibited a broader neutralizing activity spectrum than the parental sdAb monomers. The extreme stability and high recombinant production yield combined with their broad neutralization capacity make these sdAbs new potential microbicide candidates for HIV-1 transmission prevention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152508      PMCID: PMC3554102          DOI: 10.1128/JVI.00461-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.

Authors:  Yven Van Herrewege; Laurence Morellato; Anne Descours; Laetitia Aerts; Jo Michiels; Leo Heyndrickx; Loïc Martin; Guido Vanham
Journal:  J Antimicrob Chemother       Date:  2008-02-12       Impact factor: 5.790

2.  Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Authors:  Nadine Laguette; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

Review 3.  Toward an AIDS vaccine.

Authors:  Bruce D Walker; Dennis R Burton
Journal:  Science       Date:  2008-05-09       Impact factor: 47.728

Review 4.  The development of nanobodies for therapeutic applications.

Authors:  Femke Van Bockstaele; Josefin-Beate Holz; Hilde Revets
Journal:  Curr Opin Investig Drugs       Date:  2009-11

5.  Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen.

Authors:  Ghislaine Behar; Patrick Chames; Isabelle Teulon; Amélie Cornillon; Faisal Alshoukr; Françoise Roquet; Martine Pugnière; Jean-Luc Teillaud; Anne Gruaz-Guyon; André Pèlegrin; Daniel Baty
Journal:  FEBS J       Date:  2009-06-15       Impact factor: 5.542

6.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

7.  A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.

Authors:  Grégoire Martin; Yide Sun; Bernadette Heyd; Olivier Combes; Jeffrey B Ulmer; Anne Descours; Susan W Barnett; Indresh K Srivastava; Loïc Martin
Journal:  Virology       Date:  2008-10-02       Impact factor: 3.616

8.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

Review 9.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Authors:  Leonidas Stamatatos; Lynn Morris; Dennis R Burton; John R Mascola
Journal:  Nat Med       Date:  2009-08       Impact factor: 53.440

10.  Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120.

Authors:  Anna Forsman; Els Beirnaert; Marlén M I Aasa-Chapman; Bart Hoorelbeke; Karolin Hijazi; Willie Koh; Vanessa Tack; Agnieszka Szynol; Charles Kelly; Aine McKnight; Theo Verrips; Hans de Haard; Robin A Weiss
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

View more
  23 in total

Review 1.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

2.  Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites.

Authors:  Priyamvada Acharya; Timothy S Luongo; Ivelin S Georgiev; Julie Matz; Stephen D Schmidt; Mark K Louder; Pascal Kessler; Yongping Yang; Krisha McKee; Sijy O'Dell; Lei Chen; Daniel Baty; Patrick Chames; Loïc Martin; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

3.  Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Rajesh Ringe; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines       Date:  2013-07

4.  Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.

Authors:  M Bouvin-Pley; M Morgand; L Meyer; C Goujard; A Moreau; H Mouquet; M Nussenzweig; C Pace; D Ho; P J Bjorkman; D Baty; P Chames; M Pancera; P D Kwong; P Poignard; F Barin; M Braibant
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

Review 5.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

6.  Germlining of the HIV-1 broadly neutralizing antibody domain m36.

Authors:  Weizao Chen; Wei Li; Tianlei Ying; Yanping Wang; Yang Feng; Dimiter S Dimitrov
Journal:  Antiviral Res       Date:  2015-02-09       Impact factor: 5.970

7.  The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.

Authors:  Lihong Liu; Weiming Wang; Julie Matz; Chaobaihui Ye; Lucie Bracq; Jerome Delon; Jason T Kimata; Zhiwei Chen; Serge Benichou; Paul Zhou
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

8.  Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.

Authors:  Hannah J Barbian; Julie M Decker; Frederic Bibollet-Ruche; Rachel P Galimidi; Anthony P West; Gerald H Learn; Nicholas F Parrish; Shilpa S Iyer; Yingying Li; Craig S Pace; Ruijiang Song; Yaoxing Huang; Thomas N Denny; Hugo Mouquet; Loic Martin; Priyamvada Acharya; Baoshan Zhang; Peter D Kwong; John R Mascola; C Theo Verrips; Nika M Strokappe; Lucy Rutten; Laura E McCoy; Robin A Weiss; Corrine S Brown; Raven Jackson; Guido Silvestri; Mark Connors; Dennis R Burton; George M Shaw; Michel C Nussenzweig; Pamela J Bjorkman; David D Ho; Michael Farzan; Beatrice H Hahn
Journal:  MBio       Date:  2015-04-21       Impact factor: 7.867

9.  High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli.

Authors:  Kristof Zarschler; Stefanie Witecy; Franz Kapplusch; Christian Foerster; Holger Stephan
Journal:  Microb Cell Fact       Date:  2013-10-27       Impact factor: 5.328

10.  Antibody light chain variable domains and their biophysically improved versions for human immunotherapy.

Authors:  Dae Young Kim; Rebecca To; Hiba Kandalaft; Wen Ding; Henk van Faassen; Yan Luo; Joseph D Schrag; Nadereh St-Amant; Mary Hefford; Tomoko Hirama; John F Kelly; Roger MacKenzie; Jamshid Tanha
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.